To see the other types of publications on this topic, follow the link: International Resource Development, inc.
Journal articles on the topic 'International Resource Development, inc'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'International Resource Development, inc.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Hill, Christopher, and Rawy Abdelrahman Thabet. "Managing international branch campuses." International Journal of Educational Management 32, no. 2 (March 12, 2018): 310–22. http://dx.doi.org/10.1108/ijem-04-2017-0079.
Full textAbstract:
Purpose International branch campuses (IBCs) are complex entities and while much has been written about their expansion and development, the literature is largely from an external perspective. There have been few longitudinal studies examining the development of an IBC over time. The purpose of this paper is to review the development of one IBC over an eight-year time period, to identify the key learning points for institutional managers of other IBCs or for institutions intending to establish an IBC. Design/methodology/approach This paper is a culmination of research, conducted during the eight years when the lead author worked at the University of Nottingham Malaysia Campus (UNMC). The author was involved in practical management aspects as well as the research and analysis of IBC development. This paper represents a form of ethnographic research where the author conducted interviews, meetings and discussion groups, observed institutional policies, strategies and operations in action and was in an ideal position to identify and discuss their impacts on institutional performance. Findings This paper examines key management issues during the early, developing and evolving stages of an IBC and discusses key issues including communication, curriculum, identity and management. Key challenges, procedural issues, managerial responses and strategy will be presented to highlight foundational concerns for IBC development and areas and topics that must be given priority and support. Originality/value This paper considers the management of an IBC from the reflective standpoint of an author employed in a senior management position, during a period of significant growth of UNMC. The author provides insights and discussion involving practical experience.
2
Wilkins, Stephen. "Two decades of international branch campus development, 2000–2020: a review." International Journal of Educational Management 35, no. 1 (November 3, 2020): 311–26. http://dx.doi.org/10.1108/ijem-08-2020-0409.
Full textAbstract:
PurposeThe research aims to assess the achievements and challenges of international branch campuses (IBCs) to date and to consider how IBC development may progress in the future.Design/methodology/approachThe article presents a review of the scholarly and grey literatures on IBCs. The commentary and discussion is structured around the objectives, perspectives and experiences of three key stakeholder groups, namely the institutions that own IBCs, students and host countries.FindingsSome IBCs have failed to achieve their student recruitment and financial targets, while others have been successful, often expanding and moving into new, larger, purpose-built campuses. In the last few years, several countries have announced their intention to become a transnational education hub, or at least to allow the establishment of IBCs. It may be reasonable to assume that when there is demand for a product, supply will eventually follow. IBCs will survive and prosper as long as they provide benefits to each of their main stakeholder groups (i.e. students, institutions and governments), and as long as the local demand for higher education places exceeds the total supply.Originality/valueThe article provides a comprehensive and up-to-date review of IBC developments and research during the period 2000–2020. The findings and conclusions will be of interest to both researchers and practitioners.
3
Sterling, Lynn, Luc van Lonkhuijzen, Job Nyangena, Elkanah Orango, Matthew Strother, Nafthali Busakhala, and Barry Rosen. "Protocol Development for Ovarian Cancer Treatment in Kenya: A Brief Report." International Journal of Gynecologic Cancer 21, no. 2 (January 2011): 424–27. http://dx.doi.org/10.1097/igc.0b013e3182060316.
Full textAbstract:
Introduction:Ovarian cancer is a leading cause of cancer death for Kenyan women. Most women are diagnosed with an advanced stage of disease. The current North American standard of care includes surgery followed by carboplatin and paclitaxel. Neither drug is available for Kenyan women. We performed a literature search investigating chemotherapy in low-resource countries with the aim to write an evidence-based chemotherapy protocol for women diagnosed with ovarian cancer in Eldoret, Kenya, at the Moi Teaching and Referral Hospital.Methods:We systematically searched PubMed and EMBASE for articles describing chemotherapy treatment outcomes of ovarian epithelial cancer in low-resource settings. After data analysis, a secondary review was undertaken on randomized controlled trials (RCTs) aligning with chemotherapy availability in Kenya.Results:We identified 1184 articles. Fourteen met our criteria: ovarian epithelial cancer, low resource, chemotherapy use, and survival or response data. No publications were RCTs or had a cohort larger than 100 patients. There was no consistency in drug choice between studies. After this search, we reviewed commonly quoted and relevant RCTs and meta-analyses conducted on ovarian cancer since the 1980s. Although RCTs in the developed world suggest carboplatin and taxol provide optimal survival benefit, these drugs are unavailable in Kenya. Cyclophosphamide and cisplatin provide the next most optimal survival benefit, with acceptable and manageable toxicity. Because these drugs are more available and affordable in Kenya, we have developed a protocol recommending their use, which has been accepted by the Moi Teaching and Referral Hospital.Conclusions:Currently, there is a paucity of published RCTs that may guide treatment in low-resource settings. One considerable barrier to establishing and evaluating chemotherapy protocols in low-resource settings may be the cost of chemotherapy drugs. There needs to be an international movement to make cancer chemotherapeutics available at lower prices in low-resource settings.
4
Okoloise, Chairman. "“Humanizing” investments in the extractive industries in Africa through the IFC’s sustainability policies." Journal of Sustainable Development Law and Policy (The) 11, no. 1 (November 10, 2020): 106–37. http://dx.doi.org/10.4314/jsdlp.v11i1.6.
Full textAbstract:
International financial institutions face enormous challenges in Emerging Markets and Developing Economies (EMDEs). They finance infrastructure projects, manage vast investment portfolios, offer advisory services, and contribute to economic development in EMDEs. In the process, they areexposed to huge risks and face reputational damage if they act recklessly or have little or no regard for their projects’ adverse impacts on thirdparties. In the context of natural resource exploitation in Africa, the weak governance of environmental and social risks often results in devastating consequences for communities proximate to investment projects. Promises of infrastructure and social services, job opportunities and economic boom have only often delivered land grabs, forced displacement, cultural infringements, environmental pollution, conflicts, health disasters, misery and sometimes deaths. As calls for greater corporate scrutiny increase, investment project facilitators in the extractive industries like the International Finance Corporation (IFC) must respond appropriately. To preserve its reputation and long-term market access, the IFC needs to apply a higher degree of due diligence and sustainable business conduct that proactively treat risks and limit its exposure. With the rising number of complaints against IFC policy compliance, including projects tainted by scandals and the debarment of companies from accessing international finance, this article demonstrates that merely promoting sustainable investment policies on paper is inadequate. Using a human rights-centred approach to development project financing, the article critically assesses the extent to which the implementation of the IFC’s sustainability framework can practicably protect resource-rich communities, safeguard human rights and ensure sustainable development outcomes in Africa.
Keywords: Extractive Industries, Human rights, Project Financing, IFC, Compliance, Sustainable Development.
5
Nanni, Marcella, and Stephen Foster. "Groundwater resources: shaping legislation in harmony with real issues and sound concepts." Water Policy 7, no. 5 (October 1, 2005): 543–50. http://dx.doi.org/10.2166/wp.2005.0032.
Full textAbstract:
Groundwater resources are increasingly being put under pressure owing to population growth, technological progress and economic development. Many countries, however, are unable to address groundwater depletion and pollution owing to weak legal and institutional frameworks. This applies both within national contexts and in respect of international or trans-boundary aquifers (or aquifer systems). The issue is being widely debated within international fora, numbers of countries are revising their water legislation in order to include more specific provisions for groundwater, and in parallel the UN International Law Commission (ILC) is studying trans-boundary groundwater resources with a view to a codification of the law in this regard. However, the key characteristics of groundwater are often misunderstood by non-specialists and, unless resource lawyers and groundwater specialists work much more closely together, there is likelihood of erroneous interpretations of the applicable legal regime. This paper aims to highlight basic concepts and pragmatic management needs, so as to provide a framework within which national and international legislation on groundwater management and protection should be shaped.
6
Shadian, Jessica. "Remaking Arctic governance: the construction of an Arctic Inuit polity." Polar Record 42, no. 3 (July 2006): 249–59. http://dx.doi.org/10.1017/s0032247406005316.
Full textAbstract:
This article focuses on the construction of the Inuit Circumpolar Conference (ICC), the aim being to offer the historical context within which the ICC came to serve as a significant voice for Arctic policy making and as a representative of Inuit peoples in general. It explores the role of the ICC in relation to the domestic, regional, and international political events taking place during its formative years in order to provide the basis through which the ICC came to be a political authority in the Arctic. While the main coalescence of events was around the theme of Arctic resource development, each event significantly helped lay the foundation for, and structures under which, Arctic policy would proceed into the future. This includes a changing Arctic narrative that has transformed the Arctic from a being a region concentrated on resource extraction and Cold War security into a region serving as a symbolic pinnacle for global sustainable development. Through the expanded political agency of the ICC and an international focus on the Arctic, a vision of the Arctic has emerged under which it is defined by its natural environment and by the indigenous peoples who inhabit this space. This is an INDIPO project paper (Tennberg 2006).
7
Noverita, Dilla. "An Analysis of Think Globally-Act Locally Strategy Implementation in Developing Relationship of Headquarters and Subsidiaries: Case Study of John Clements Consultants Inc., Philippines & Indonesia." Gadjah Mada International Journal of Business 9, no. 1 (January 12, 2007): 101. http://dx.doi.org/10.22146/gamaijb.5601.
Full textAbstract:
John Clements Consultants Inc. (JCCI) is a long established and the largest consulting company in Philippines. Its main business focuses on human resource development, especially recruitment and training. Headquarters is in Philippines and its business has grown throughout the world, especially in the Asia-Pacific, Middle-East and United States. As a multinational company, JCCI has to maintain and develop the relationship with all subsidiaries efficiently. In this case, using qualitative approach and focusing on the relationship with Indonesian subsidiary, this research assesses how headquarters of JCCI formulates and implements company policies governing the relationship between headquarters and subsidiaries. It explores how the headquarters controls, communicates, makes decisions, plans strategy, and gives authority to the subsidiaries. Moreover, this research analyses how JCCI applies “think globally – act locally” strategy in its global operations and developing relationship with subsidiaries. It brings the issues of all challenges and obstacles the company has in dealing with subsidiaries. Finally, this research recommends alternative strategies to leverage the relationship between headquarters and subsidiaries more efficiently and to minimize the obstacles in cross-cultural management so that the company will be able to strengthen its position in global service market.
8
Kostyuchenko, N., and A. Zakorko. "TRANSNATIONAL COMPANIES’ STRATEGIC PLANNING IN THE CONTEXT OF THE GLOBAL SUSTAINABLE DEVELOPMENT GOALS." Vìsnik Sumsʹkogo deržavnogo unìversitetu, no. 4 (2019): 114–22. http://dx.doi.org/10.21272/1817-9215.2019.4-15.
Full textAbstract:
The paper is dedicated to the investigation of the impact of the Global Sustainable Development Goals on the strategic planning of transnational corporations and their competitiveness. The object of the paper is transnational corporations in the sector of fast-moving consumer goods, particularly: Danone S.A., Kraft Heinz, PepsiCo Inc., the Coca Cola company, Unilever PLC, P&G, Johnson& Johnson, Mondelez International, Nestle S.A., Philip Morris International, British American Tobacco. The article focuses on analysis of fast-moving consumer goods’ sector and examines the relevance of the companies’ activities to the Global Sustainable Development Goals. The role of “green” investments for competitiveness of transnational corporations has been identified. The information base of the paper is the United Nations’ information materials, Forbes information resources, the statistical data of NASDAQ, publications of famous audit and consulting companies (Deloitte, KPMG, PwC), transnational companies’ official reports, and scientific papers of Ukrainian and foreign researches. A rank of scientific research methods was applied in the paper: descriptive method - for general analysis of transnational companies’ strategic planning; analytical method and comparative method - for evaluation and analysis of transnational corporations’ stock prices and market capitalization in the fast-moving consumer goods’ sector; system analysis - for identification of the key characteristics of strategic planning of transnational corporations in the context of the Global Sustainable Development Goals. The authors propose recommendations that can be used while creating strategies for the development of international companies, including transnational corporations, as well as while analyzing the compliance of existing companies' strategies with the Global Sustainable Development Goals. Keywords: fast-moving consumer goods’ market, Global Report Initiative, Global Sustainable Development Goals, strategic planning, transnational corporations.
9
Sadosky, A., P. Schepman, S. Thakkar, R. Robinson, and C. Beck. "AB0035 A REVIEW OF THE CLINICAL AND ECONOMIC BURDEN OF OSTEOARTHRITIS PAIN BY SEVERITY IN THE UNITED STATES." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1050.2–1051. http://dx.doi.org/10.1136/annrheumdis-2021-eular.534.
Full textAbstract:
Background:The development of new therapies to treat symptomatic osteoarthritis (OA) often requires targeting patient subgroups such as mild and/or moderate and/or severe. Multiple assessments for pain are used in clinical and research settings, yet to quantify patient burden with increasing pain severity it is important to understand the potential variability in outcomes based on definitions of severity used1.Objectives:The objective of this study was to examine studies in the published literature that report the burden of OA pain by severity to assess similarities and/or differences across study methodologies and outcomes.Methods:A targeted literature review of PubMed and Google Scholar was conducted January 2021 and included search terms: osteoarthritis, severity, United States (US), burden, quality of life, medication/treatment, and healthcare resource utilization. The search was limited to the English language, full-text articles, and no restriction on publication date. Results included a recent study of the burden of symptomatic OA pain respondents by severity level in the US2,3. Over 100 publication titles were reviewed. Comparison of findings was descriptive in nature.Results:Nine publications were identified representing 7 unique studies, 6 being patient and/or healthcare provider surveys. Two studies focused on OA severity: the remaining 5 stratified patients by pain severity, and all but 2 of the 5 identified and confirmed pain as OA-related. Pain measures included numeric rating scales (generic 0-10, Western Ontario and McMaster Universities Arthritis Index [WOMAC] NRS 3.1), visual analog scales (generic 0-100, Short-Form McGill Pain Questionnaire Visual Analog Scale [SF-MPQ-VAS]) or Pain Interference with Activities (PIA) scale derived from the 12-Item Short Form Health Survey [SF-12v2] developed for the Medical Outcomes Study, with recall periods varying from 48 hours to 7 days to 4 weeks. Only one study exclusively assessed symptomatic patients only i.e., patients with pain scores of 0 were excluded; the remainder compared cohorts of no/mild pain with increasing severity cohorts. Four of the 7 studies examined pairwise differences among mild, moderate, and severe patients (1 study vs. a non-OA cohort); 2 compared no/mild vs. moderate-to-severe OA pain and 1 study compared mild to moderate-to-severe OA pain. For most outcomes examined like clinical comorbidities, quality of life, and healthcare resource utilization, increasing burden was observed with increasing OA and/or pain severity despite study variability.Conclusion:Pain severity levels represent an important and distinguishing factor that contributes to health outcomes in OA patients in the US. Considerable heterogeneity across studies may impact how OA pain is defined, perceived by patients, and treated. Selecting appropriate OA pain severity assessments, including cut-points, may contribute to the successful monitoring of outcomes or comparisons of therapies to manage symptomatic OA pain, especially those that target specific pain severity subgroups.References:[1]Hawker GA, Mian S, Kendzerska T et al. Arthritis Care and Research. 2011; 63(11):S240-S252.[2]Schepman P, Robinson RL, Thakkar S, et al. International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Virtual Annual Meeting; May 2020.[3]Schepman P, Thakkar S, Robinson RL, et al. PAINWeek 2020 Virtual Meeting; September 2020.Disclosure of Interests:Alesia Sadosky Shareholder of: Own stock in Pfizer Inc, Consultant of: I am an employee with the consulting firm Apperture Health, Employee of: I am retired from Pfizer Inc, Patricia Schepman Shareholder of: Owns shares in Pfizer Inc, Employee of: Employee of Pfizer Inc, Sheena Thakkar Shareholder of: Owns shares of Pfizer Inc, Employee of: Employee of Pfizer Inc, Rebecca Robinson Shareholder of: Owns shares of Eli Lilly and Company, Employee of: Employee of Eli Lilly and Company, Craig Beck Shareholder of: Owns shares of Pfizer Inc, Employee of: Employee of Pfizer Inc
10
Priya, Ritu, and Chris M. Kurian. "Regulating Access and Protecting Traditional Health Knowledge through Intellectual Property Rights? Issues from a Holistic Health Systems Perspective." Science, Technology and Society 23, no. 3 (May 2, 2018): 504–29. http://dx.doi.org/10.1177/0971721818762937.
Full textAbstract:
Traditional Health Knowledge (THK) has been a resource for modern pharmacology and the pharma-ceutical industry since its inception. Until the 2000s, there was little obligation to acknowledge the use of THK by the pharmaceutical industry. Now, with the intellectual property regime becoming a prominent mode of regulating use of pharmaceutical inventions and innovations, and attempts by the pharmaceutical industry to patent products based on THK, rights of THK holders are being fore-grounded. The World Intellectual Property Organization (WIPO) is seeking to protect the rights of THK holders through international legal instruments under the Intellectual Property Rights (IPR) framework. This article discusses dilemmas arising from this attempt at bringing together two diverse knowledge frameworks. It draws upon existing literature on the nature of THK and upon the debates of the WIPO’s Inter-Governmental Committee on Genetic Resources, Traditional Knowledge and Traditional Cultural Expression (WIPO-IGC), and analyses them from the standpoint of a holistic health systems approach (HHSA) in an era of Sustainable Development Goals (SDGs). The approach leads to the conclusion that deliberations and promulgations of the WIPO-IGC will have long-lasting implications for the survival of diversity and context-specificity in healthcare. Therein lies the significance of thinking through the policy and legal measures to be adopted nationally and internationally.
11
Nish, Ian. "American, Chinese and Japanese Perspectives on Wartime Asia, 1931–1949. Edited by Akira Iriye and Warren Cohen. [Wilmington: Scholarly Resources Inc., 1990. 308 pp. $40.00.]." China Quarterly 132 (December 1992): 1183–84. http://dx.doi.org/10.1017/s0305741000045690.
Full text
12
Baker, Hugh D. R. "The Chinese Recorder Index: A Guide to Christian Missions in Asia, 1867-1941, 2 Vols. By Lodwick Kathleen. [Delaware: Scholarly Resources Inc., 1986. $150 00.]." China Quarterly 109 (March 1987): 139–40. http://dx.doi.org/10.1017/s0305741000017689.
Full text
13
Cruz, Rodolfo Cerdas. "Richard V. Salisbury, Anti-Imperialism and International Competition in Central America, 1920–1929 (Wilmington, Dela.: Scholarly Resources Inc., 1989), pp. xiii + 181, $30.00." Journal of Latin American Studies 22, no. 1-2 (March 1990): 194–96. http://dx.doi.org/10.1017/s0022216x00015248.
Full text
14
Dzharova, Hristina Kostadinova, Sudheer Gupta, and Jai Ganesh. "WaterHealth International in India: crafting sustainable solutions for potable water." CASE Journal 12, no. 2 (May 5, 2016): 156–68. http://dx.doi.org/10.1108/tcj-08-2014-0056.
Full textAbstract:
Synopsis The case features WaterHealth International India (WHIN) – a subsidiary of WaterHealth International (WHI) Inc. WHIN was launched in 2006 with the vision to “be the leader in providing scalable, safe, and affordable water solutions to underserved populations through an innovative business model.” The company incorporated a Build-Operate-Transfer model with decentralized production and distribution. Following a successful pilot project, WHIN installed its WaterHealth Centers in 175 sites throughout rural India by 2009, and attracted a $15 million investment from the International Finance Corporation to further expand its operations in India. Mr Vikas Shah, the Chief Operating Officer of the company, is faced with the issue of assessing scalability and sustainability of the company's business model. He needs to examine and evaluate the company's value proposition, resources and capabilities, and decide how to generate economic value while maintaining a focus on its social vision. The latter entails an ability to create shared value for stakeholders as an important contributor toward the company's sustainability. Additionally, Mr Shah is evaluating alternative public-private partnerships in terms of their suitability for the Indian context and viability to drive profitability. Research methodology The case uses primary and secondary data, i.e. interviews with company representatives, company reports, presentations, and consulting papers. Relevant courses and levels The case is written for graduate (and advanced undergraduate) students that enroll in classes with a focus on emerging markets, sustainability, innovation, and entrepreneurship. Examples are courses in Entrepreneurship and Innovation (especially those that include one or more sessions on the social dimensions) as well as those in Inclusive Growth and Sustainable Development.
15
Djohor, Denny Suwanda, and Harry Pramudito. "KARAKTERISTIK BATUBARA FORMASI WARUKIN DALAM PEMBENTUKAN CBM DI WILAYAH KABUPATEN TANAH BUMBU, PROVINSI KALIMANTAN SELATAN." PENELITIAN DAN KARYA ILMIAH 2, no. 1 (January 1, 2018): 14. http://dx.doi.org/10.25105/pdk.v2i1.2455.
Full textAbstract:
Increasing world oil prices have a huge impact on national energy needs. Indonesia's economic growth requires the development of alternative energy sources based on 10 basin assessments in Indonesia, coal methane gas potential is estimated to reach 337 TCF of gas in place (Advanced Resources International, inc). The research location is located in the Basin of Asam-Asam,South Kalimantan. Targeted research on the Miocene Warukin Formation. The data used to evaluate Coal Methane Gas potential include surface geology data and coal sample analysis, as well as characteristics of regional anomaly bouger for South Kalimantan. The development of cleats and fractures in coal at the observation site can be classified into high-intensity vitamite-rich coal categories. Coal Warukin Formation has an average Rv value = 0.56% with standard deviation 0.02%. and is ranked in sub-bituminous coal rank. While for other Warukin Formation coal has an average Rv value = 0.58% and entered in rank (bit) bituminous coal with type of methane gas is the type of bio & thermogenic gas mixture. When viewed from the thick layer of coal and gas type, the Warukin Formation coal in the location of research is quite interesting when included in the coal resources of economical coal methane gas.
16
Campbell, A. K. R. "Conquering Resources: The Growth and Decline of the PLA's Science and Technology Commission for National Defense. By Benjamin C. Ostrov. [Armonk, New York & London: M. E. Sharpe, Inc., 1991. 156pp. $45.00.]." China Quarterly 131 (September 1992): 828–29. http://dx.doi.org/10.1017/s030574100004666x.
Full text
17
Smaliukiene, Rasa, Lai Chi-Shiun, and Indre Sizovaite. "CONSUMER VALUE CO-CREATION IN ONLINE BUSINESS: THE CASE OF GLOBAL TRAVEL SERVICES." Journal of Business Economics and Management 16, no. 2 (December 16, 2014): 325–39. http://dx.doi.org/10.3846/16111699.2014.985251.
Full textAbstract:
This paper aims to examine the application of value co-creation approach in online travel service based on service-dominant logic. Drawing on recent works, the research indicates travellers as co-creators of value and emphasizes the development of customer–supplier interaction. The paper presents three case studies to analyse global travel service suppliers’ (service providers) behaviour: CouchSurfing International, Inc.; TripAdvisor LLC, AirBnbINc. Case studies analysis is followed by netnographic research of 22 different discussions (1243 records) in online forums related to selected service suppliers. The research findings suggest that value co-creation approach can be effectively used to analyse processes in global online travel service section. The originality of the paper lies in exploring the contribution of co-creation approach which allowed to identify the patterns of actions and behaviour of the online travel service providers and their consumers. As an additional value of the research, it was found that the online travel service providers integrate customer-to-customer interactions as a value co-creation in their platforms using consumers’ resources such as time, knowledge and experience.
18
Aljama, Mohammed A., M. Hasib Sidiqi, Arjun Lakshman, Angela Dispenzieri, Dragan Jevremovic, Morie A. Gertz, Martha Q. Lacy, et al. "Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma." Blood 132, Supplement 1 (November 29, 2018): 3160. http://dx.doi.org/10.1182/blood-2018-99-114882.
Full textAbstract:
Abstract The plasma cell proliferative index (PCPI) provides an insight into plasma cell biology in plasma cell disorders. It recognizes cells that are actively synthesizing DNA and gives an indication of the proliferative rate of the malignant plasma cells.The PCPI has been shown to be a prognostic tool in patients with multiple myeloma and amyloidosis. We conducted a retrospective review analyzing the prognostic impact of PCPI in 306 patients with smoldering multiple myeloma (SMM). The median age was 66 (56-73) years and 61% (n=186) were males. The median follow-up for the entire cohort was 10.2 years (95% confidence interval: 9.0-10.9). One-hundred sixty-nine (55%) patients were alive at the time of study analysis while 118 (39%) had progressive disease. The median time to progression was 5.9 years (95% confidence interval: 4.8-8.2). Symptomatic events at the time of progression included anemia in 41% (n=48), bone complications in 37% (n=44), renal complications in 9% (n=11), hypercalcemia in 2% (n=2) and development of amyloidosis in 2% (n=2). Seventeen patients (14%) were categorized as having progression due to rapid progressive elevation in the serum free light chains (sFLC) and/or progressive increase in the size of their M-spike. The median time between the diagnosis and PCPI date was 0 months (interquartile range 0-1). An elevated PCPI was defined as a level >0.5%. Seventy-nine (26%) patients had an elevated PCPI. Patients with an elevated PCPI were significantly older (median age: 69 years for elevated PCPI vs 64 years for low PCPI (p= 0.008) and predictably had more proliferative disease with a higher rate of patients with bone marrow plasma cells >20% (48% for elevated PCPI vs 34% for low PCPI, p=0.03). An elevated PCPI predicted a shorter time to progression (TTP); median 3.0 years versus 7.1 years for those with a low PCPI (p= 0.0004). Within 24 months, the progression rate was significantly higher for patients with an elevated PCPI; 49% versus 20% (p<0.0001). We constructed two multivariable models using the conventional and recently proposed Mayo risk stratification tools. In both models, an elevated PCPI was an independent predictor of to multiple myeloma. PCPI is a valuable tool in risk stratifying patients with SMM and identifies patients with earlier progression who may benefit from closer follow up and consideration of early intervention trials. Disclosures Dispenzieri: Celgene, Takeda, Prothena, Jannsen, Pfizer, Alnylam, GSK: Research Funding. Gertz:Research to Practice: Consultancy; spectrum: Consultancy, Honoraria; Abbvie: Consultancy; Amgen: Consultancy; janssen: Consultancy; Physicians Education Resource: Consultancy; Teva: Consultancy; celgene: Consultancy; annexon: Consultancy; Alnylam: Honoraria; Prothena: Honoraria; Medscape: Consultancy; Apellis: Consultancy; Ionis: Honoraria. Lacy:Celgene: Research Funding. Dingli:Alexion Pharmaceuticals, Inc.: Other: Participates in the International PNH Registry (for Mayo Clinic, Rochester) for Alexion Pharmaceuticals, Inc.; Millennium Takeda: Research Funding; Alexion Pharmaceuticals, Inc.: Other: Participates in the International PNH Registry (for Mayo Clinic, Rochester) for Alexion Pharmaceuticals, Inc.; Millennium Takeda: Research Funding. Kapoor:Celgene: Research Funding; Takeda: Research Funding. Kumar:Oncopeptides: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda: Membership on an entity's Board of Directors or advisory committees; Merck: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Research Funding; KITE: Membership on an entity's Board of Directors or advisory committees, Research Funding; KITE: Membership on an entity's Board of Directors or advisory committees, Research Funding.
19
Hunter, Alan. "Christianity in China: A Scholars' Guide to Resources in the Libraries and Archives of the United States. By Archie R. Crouch, Steven Agoratus, Arthur Emerson and Debra E. Soled [Armonk, New York & London: M. E. Sharpe Inc., 1989. 709 pp.]." China Quarterly 125 (March 1991): 181–82. http://dx.doi.org/10.1017/s0305741000030587.
Full text
20
To Dutka, Julia, Mark Kovic, Kristen Mauk, and Richard Oliver. "Global Certification: A Transformative Approach to Building the World’s Rehabilitation Health Workforce." Journal of Rehabilitation Therapy 3, no. 1 (July 21, 2021): 21–30. http://dx.doi.org/10.29245/2767-5122/2021/1.1126.
Full textAbstract:
To meet the needs of the 2.41 billion people seeking rehabilitation care, the world’s health workforce must be sustainable and scalable. In 2021, the WHO launched its Rehabilitation Competency Framework (RCF) to help countries build local rehabilitation ecosystems by focusing on high-level priorities. A top priority is the development of a health workforce that is sustainable and scalable to meet local needs. To capitalize on existing health workforce resources, countries need to focus on the specialists and on other members of the rehabilitation team who can assume targeted responsibilities for delivering care. To support these efforts, CGFNS International, Inc., an assessment organization for health professionals worldwide, is developing two exam-based global certifications, one for rehabilitation health workers and one for registered nurses working in rehabilitation settings. These global certifications assess the knowledge and competencies of individual rehabilitation health workers and nurses and certify those who meet the standards. For consumers, global certification attests to the competence of local service providers and helps ensure quality care. For health workers and nurses, global certification confers a credential that recognizes their expertise and supports their continuing professional development and career goals. And for policymakers, global certification provides useful information for managing care delivery. This article provides the rationale behind global certification, describes the methodology for creating these certifications, and shows how their underlying constructs and those of the WHO’s RCF align. This alignment helps consumers, health workers and nurses, and local authorities use all available tools to make informed decisions advancing rehabilitation care.
21
Schleimer, Lauren E., Nancy L. Keating, Lawrence N. Shulman, Ben O. Anderson, Catherine Duggan, Daniel S. O’Neil, and Lydia E. Pace. "Review of Quality Measures for Breast Cancer Care by Country Income Level." Journal of Global Oncology 4, Supplement 3 (October 2018): 41s. http://dx.doi.org/10.1200/jgo.18.10480.
Full textAbstract:
Purpose Measurement of the quality of cancer care is essential for quality improvement and is widely implemented in oncology programs in high-income countries. Growing efforts are being made to measure care quality in emerging cancer care delivery systems in low- and middle-income countries (LMICs). This will require the development of measures that are clinically important, actionable, relevant to existing resources, and feasible to routinely evaluate. As part of a project to develop resource-adapted quality measures for Rwanda and other LMICs, we conducted a systematic review of the literature to identify published quality measures for the diagnosis and treatment of breast cancer. Methods We performed a literature search in accordance with PRISMA guidelines using the following terms in PubMed: ‘breast cancer’ and ‘quality indicator,’ ‘quality measure,’ or ‘quality metric’; and the following MeSH terms: ‘breast neoplasms’ and ‘healthcare quality indicator.’ We included English-language articles published before August 2017 that described the systematic identification of process measures for breast cancer diagnosis or treatment through literature review, clinical validation, and/or expert panel determination. We directly searched the Web sites of prominent cancer care organizations to identify additional publicly available measures. Income level was classified using World Bank definitions. Results We identified 521 published quality measures, including 419 measures from 27 peer-reviewed journal articles and 102 measures from the Web sites of national and international cancer care organizations. Twenty-five peer-reviewed publications (93%) originated from high-income countries, one from an upper-middle income country (People’s Republic of China), and one from the international Breast Health Global Initiative with process measures to assess the phased implementation of breast cancer services. No resources or articles other than that from the Breast Health Global Initiative provided suggestions for adapting measures to limited resources. Conclusion A large number of quality measures for breast cancer care have been identified and published in high-income countries; however, no breast cancer care quality measures have been systematically developed and validated for use in settings where resource limitations crucially affect care delivery and measurement feasibility. We are collaborating with clinicians in LMICs and global breast cancer experts to develop and validate quality measures that will enable quality improvement initiatives in Rwanda and other emerging cancer care delivery systems. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc . No COIs from the authors.
22
Kaufman, George G. "Emerging Economies and International Financial Centers." Review of Pacific Basin Financial Markets and Policies 04, no. 04 (December 2001): 365–77. http://dx.doi.org/10.1142/s0219091501000577.
Full textAbstract:
A number of emerging economies are considering directing public resources to developing an international financial center (IFC). They are doing so because of the perceived advantages of IFCs, including high value added, quick development, and low fixed-cost plant and equipment. But being an IFC also has costs, including high fragility, spillover of problems from the center to the domestic economy, and quick departure of footloose human capital. This paper evaluates the benefits and costs of becoming an IFC, enumerates the characteristics of IFCs, traces the history of IFCs, and describes recent changes in the ranking of major IFCs. It concludes that this may not be an opportune time for emerging economies to devote public resources to developing an IFC.
23
Gibbs, Nikki. "Reviewer Acknowledgements." Applied Economics and Finance 5, no. 3 (April 26, 2018): 116. http://dx.doi.org/10.11114/aef.v5i3.3250.
Full textAbstract:
Applied Economics and Finance (AEF) would like to acknowledge the following reviewers for their assistance with peer review of manuscripts for this issue. Many authors, regardless of whether AEF publishes their work, appreciate the helpful feedback provided by the reviewers. Their comments and suggestions were of great help to the authors in improving the quality of their papers. Each of the reviewers listed below returned at least one review for this issue.Reviewers for Volume 5, Number 3Aaron Morey, University of Melbourne, AustraliaAli Massoud, Sohag University, EgyptAndrey Kudryavtsev, The Max Stern Yezreel Valley Academic College, IsraelAsad K. Ghalib, Liverpool Hope University, UKDilshodjon Rakhmonov, Tashkent State University of Economics, UzbekistanEncarnación Alvarez-Verdejo, University of Granada, SpainEyup Kadioglu, Capital Markets Board, TurkeyFarhat Iqbal, University of Balochistan, Quetta – Pakistan. , Pakistan.He Nie, Jinan University, ChinaIbrahim Baghdadi, Lebanese University, LebanonIgor Matyushenko, School of Foreign Economic Relations and Touristic Business, UkraineMagdalena Radulescu, University of Pitesti, RomaniaMagdalena Zioło, University of Szczecin, PolandMarwa Biltagy, Cairo University, Faculty of Economics and Political Science, EgyptMohammed Al-Mahish, King Faisal University, Saudi ArabiaMojeed Idowu John Odumeso-Jimoh, Noble Integrated Resources & Management, NigeriaNuno Crespo, ISCTE-IUL, PortugalPatrycja Kowalczyk-Rolczynska, Wroclaw University of Economics, PolandProf. Aloysius Ajab AMIN, Institute for Development Solutions, Inc, USARamona Orastean, Lucian Blaga University of Sibiu, RomaniaRichard Nguyen, Alliant International University, USARomeo Victor Ionescu, Dunarea de Jos University, RomaniaSherry Jensen, Florida Institute of Technology, USASteven V. Cates, Kaplan University, USASzabolcs Blazsek, Universidad Francisco Marroquín, Guatemala Nikki GibbsEditorial AssistantOn behalf of,The Editorial Board of Applied Economics and FinanceRedfame Publishing9450 SW Gemini Dr. #99416Beaverton, OR 97008, USAURL: http://aef.redfame.com
24
Fischer, Arthur K. "Midwest Education, Inc.: An International Human Resource Management Case Study." Journal of Business Case Studies (JBCS) 1, no. 1 (January 1, 2005): 47–54. http://dx.doi.org/10.19030/jbcs.v1i1.4915.
Full text
25
Fielding, Lawrence W., Lori K. Miller, and James R. Brown. "Harlem Globetrotters International, Inc." Journal of Sport Management 13, no. 1 (January 1999): 45–77. http://dx.doi.org/10.1123/jsm.13.1.45.
Full textAbstract:
Case studies form the basis for the development of what business scholars have termed best practices scenarios. The Harlem Globetrotters International (HGI) is one of the most successful sport franchises in history. In this case study, we trace the development of HGI, from its beginnings in 1926 to its acquisition in 1993 by present owner and CEO, Mannie Jackson. We present a situational analysis of HGI from Jackson's perspective at the time of purchase. Next we outline Jackson's vision, objectives, and competitive strategy. We present Jackson's strategic brand management tactics. Next, we present Jackson's interpretation of the success of HGI's strategy and his interpretation of HGI's strengths, weaknesses, threats, and positive outlook. Appendix H presents relevant financial data that can be used to analyze HGI's success and shortcomings. Appendix I presents discussion questions. This case study is intended to be used as a teaching tool.
26
Garcia-Manero, Guillermo, Michael E. Petrone, Steven M. Fruchtman, Bernard Brownstein, Hannes Loferer, Nozar Azarnia, Shireen Vali, et al. "Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-Risk MDS: Simulation of a Predictive Signature for Clinical Response." Blood 128, no. 22 (December 2, 2016): 4324. http://dx.doi.org/10.1182/blood.v128.22.4324.4324.
Full textAbstract:
Abstract Background: MDS is a marrow stem cell disorder with limited treatments. Due to outcome heterogeneity of MDS, it is imperative to identify prognostic tools for patients in clinical trials. Rigosertib (RIG) is a RAS-mimetic that inhibits cellular signaling pathways by binding to the RAS-binding Domain found in RAS effector proteins. No approved treatment options are available for Higher-risk myelodysplastic syndromes (HR-MDS) pts after Hypomethylating Agent (HMA) failure. The "ONTIME" trial was a Phase III, randomized study of rigosertib in a heterogeneous population of HR-MDS pts who failed to respond to or progressed on HMAs. Aim: To determine the predictive value of a genomics-informed computational biology method and to design a patient selection signature in HR-MDS patients who are treated with RIG. Methods: ONTIME trial included HR-MDS pts who had progressed on (37% of total enrollment), failed to respond to (25%), or relapsed after (38%) HMA treatment. Patients were randomized 2:1 to receive RIG (199 pts) or best supportive care (BSC) (100 pts) (Garcia-Manero et al, Lancet Oncology, 2016).The primary endpoint was overall survival, analyzed on an intention-to-treat basis using the Kaplan-Meier method. Genomic DNA was isolated from single microscopic slides from 153 pts and subjected to sequence analysis of a "myeloid panel" comprising of 24 selected loci frequently mutated in MDS and AML. Standardized cytogenetic investigations were performed. The chromosome aberrations and clone definition followed the International System for Cytogenetic Nomenclature. Depending on the aberrations detected during karyotyping, further probes were applied. A complex karyotype was defined as ≥3 independent aberrations within 1 clone. These genomic results were input into predictive computational biology software (Cellworks Group, Fig. 1), which generates disease-specific dysregulated protein network maps using PubMed and other resources. Digital drug simulations are conducted by quantitatively measuring drug effect on a cell growth score, which is a composite of cell proliferation, viability and apoptosis. Each patient-specific protein network map was digitally screened for the extent by which RIG reduced disease growth in a dose-respondent manner. Clinical outcomes were prospectively recorded. Results: Based on input data from cell-culture studies the predicted response was blindly correlated with the clinical outcome for 54 patients with the following predictive test statistics: positive predictive value (PPV) - 85%, negative predictive value (NPV) - 94.12%, Sensitivity - 89.47%, Specificity - 91.43% and an accuracy of the predictive test at 90.74%. The accuracy of the genomics-informed computer method was significantly greater than empiric drug administration. New genomic signature rules were discovered to correlate with clinical response after RIG treatment. The predictive computational analysis identified a novel signature for selecting HR-MDS patient's responding to RIG. We identified patients with either trisomy 8 or trisomy 21 that also do not have any of the following aberrations including: Del 5q or Del 7/7q or Del 3 or Del 14 or Del 16 or Del 20, would be responders to the drug (Trisomy 8 OR Trisomy 21) AND NOT (Del 5 q OR (Del 7/7q OR Del 3 OR Del 14 or Del 16 or Del 20). We validated this patient selection rule prospectively via statistical correlation methods and through a computer based simulation of a clinical trial generated predicted Kaplan-Meir curve with a significant p-value of 0.003 (Fig. 2). Conclusions: A predictive computational method that models multiple high-risk MDS genomic abnormalities simultaneously showed greater than 90% correlation between protein network perturbations and clinical outcomes. The computational method also helps explain reasons for lack of response to RIG and highlights resistance pathways that could be targeted to recover chemo-sensitivity. This technology also established eligibility criteria for precision enrollment in drug development trials. Figure 1 Figure 1. Figure 2 Figure 2. Disclosures Petrone: Onconova Therapeutics, Inc.: Employment. Fruchtman:Onconova: Employment. Brownstein:Onconova Therapeutics, Inc.: Consultancy. Loferer:Onconova Therapeutics, Inc.: Employment. Azarnia:Onconova Therapeutics, Inc.: Employment. Vali:Cellworks Group: Employment. Singh:Cellworks Group: Employment. Usmani:Cellworks: Employment. Grover:Cellworks Group: Employment. Abbasi:Cellworks: Employment. Silverman:Onconova Therapeutics, Inc.: Patents & Royalties: Co-Patent holder for the combination of azacitidine and rigosertib, Research Funding.
27
Macdonald, R. ST J. "Charles B. Bourne: Scholar, Teacher, and Editor, Innovator in the Development of the International Law of Water Resources." Canadian Yearbook of international Law/Annuaire canadien de droit international 34 (1997): 3–88. http://dx.doi.org/10.1017/s0069005800006329.
Full textAbstract:
SummaryThe author traces the career of one of Canada’s leading international lawyers as a teacher of international law, as the founding editor and editor-in-chief of thisYearbookfor thirty years, and as a scholar in the field of the international law of water resources. Bourne’s role in the development of the Helsinki Rules is recounted and hü fundamental difference with the work of the ILC over the competing principles of “equitable utilization” and “no appreciable harm” is analyzed.
28
Metcalfe, Beverly Dawn, and Christopher J. Rees. "Theorizing advances in international human resource development." Human Resource Development International 8, no. 4 (December 2005): 449–65. http://dx.doi.org/10.1080/13678860500354601.
Full text
29
Lauterpacht, E. "Law and Policy in International Resource Development." Journal of Energy & Natural Resources Law 11, no. 3 (August 1993): 145–54. http://dx.doi.org/10.1080/02646811.1993.11432958.
Full text
30
Rifkin, Robert M., Faith E. Davies, Antonio Palumbo, Jeffrey Zonder, Saulius K. Girnius, Caitlin L. Costello, Saad Z. Usmani, et al. "Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study." Blood 128, no. 22 (December 2, 2016): 5681. http://dx.doi.org/10.1182/blood.v128.22.5681.5681.
Full textAbstract:
Abstract Advances in novel agents and treatment combinations have improved prognosis and increased disease-free and overall survival for patients (pts) with multiple myeloma (MM). However, currently available data on disease presentation, treatment patterns, and outcomes for real-world MM pts at the global level are limited. This is due to several factors, including the overrepresentation of medically fit pts in clinical trials making generalization of outcomes challenging, the large number of treatment combinations, and varying global access/practice patterns. INSIGHT-MM (NCT02761187) is a global, prospective, non-interventional, observational study which aims to further understand disease and pt characteristics at presentation, treatment and clinical outcomes of real-world MM pts, as well as the association of treatment with tolerability, effectiveness, health-related quality of life (HRQoL), and healthcare resource utilization (HRU), on both a country-specific and global basis. As this is an observational study, no formal hypothesis will be tested. The INSIGHT-MM objectives are summarized in the Table. At least 5000 pts aged ≥18 yrs with newly diagnosed or relapsed/refractory MM will be enrolled over a 3-yr period and followed prospectively for ≥5 yrs, until death or end of study, whichever comes first. Pts not available for data collection for >9 mos will have follow-up for survival. No study drug or medications will be provided; no modification of standard of care pt management will be assigned per protocol. Choice of therapy for all pts will be decided by the treating healthcare provider independent of study participation. Baseline pt and MM-specific characteristics, diagnosis, comorbidities, and prior therapies will be recorded based on review of hospital/clinic records. MM management, disease status and safety data will be obtained as part of routine office visits and recorded quarterly by each site in electronic case report forms. Quarterly assessment of MM management will be done based on prior and current treatment and recorded reason for treatment changes. Effectiveness of therapy will be assessed based on response, progression status, time to next therapy, vital status, and date and cause of death. Treatment tolerability will be assessed based on serious and non-serious adverse events leading to treatment discontinuation or dose modification. Incidence of second primary malignancies will be recorded. HRQoL, a specific type of patient reported outcome (PRO), will be collected at study entry and at predefined intervals following initiation of therapy using a secure electronic data collection system. HRQoL will be collected using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and the MM module (EORTC QLQ-MY20). To capture pt satisfaction with MM-directed therapy, including the dimension of convenience, the 9-item Treatment Satisfaction Questionnaire for Medication will be used. The 5-dimension, 5-level EuroQol (EQ-5D-5L) PRO instrument will capture self-reported preference-based measures of health status suitable for calculating quality-adjusted life year (QALY) data to inform health economic evaluations. Frailty will be assessed using the Charlson Comorbidity Index, the Katz Index of Independence in Activities of Daily Living, and the Lawton Instrumental Activities of Daily Living. HRU will be evaluated using inpatient and intensive care unit admissions, length of stay, outpatient clinic visits, and emergency room visits. Data for all participating pts will be extracted by healthcare professionals at the site level and entered into a central database; descriptive statistical analyses will be done to address the study objectives. Interim analyses are planned after 1000 and 5000 pts have been enrolled and a final analysis will be conducted within 1 year after the last pt entered has completed ≥5 yrs follow-up. Data will be analyzed biannually to address emerging clinical questions identified by investigators to increase understanding of real-world treatment patterns. INSIGHT-MM aims to promote better understanding of contemporary demographics, patterns of care, and outcomes for real-world MM pts to inform treatment practice, supportive care, and pt outcomes. The study is currently ongoing and recruiting pts; further details regarding study rationale and protocol will be provided. Table 1 Table 1. Disclosures Davies: Takeda: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Janssen: Consultancy, Honoraria. Palumbo:Janssen Cilag: Honoraria; Takeda: Employment, Honoraria. Zonder:Bristol Myers Squibb: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Prothena: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Pharmacyclics: Other: DSMC membership. Girnius:Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Speakers Bureau. Costello:Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Usmani:Array: Research Funding; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Millenium: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Onyx: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; BioPharma: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pharmacyclics: Research Funding; Britsol-Myers Squibb: Consultancy, Research Funding; Skyline: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Speakers Bureau. Berdeja:Abbvie, Acetylon, Amgen, Bluebird, BMS, Calithera, Celgene, Constellation, Curis, Epizyme, Janssen, Karyopharm, Kesios, Novartis, Onyx, Takeda, Tragara: Research Funding. Omel:Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Member of Takeda's "Patient Leadership Council". Token payment. Thompson:Celgene: Membership on an entity's Board of Directors or advisory committees, Other: MDS/AML Registry; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; AIM Specialty Health: Membership on an entity's Board of Directors or advisory committees; VIA Oncology: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees, Other: Multiple Myeloma International Registry; Doximity: Equity Ownership, Membership on an entity's Board of Directors or advisory committees. Shah:Array: Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria, Research Funding; Bristol-Myers Squibb: Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Schwartz:Bayer: Consultancy; Blue Cross and Blue Shield Associations: Consultancy; Pfizer: Consultancy; Takeda: Consultancy. Hajek:Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees. Terpos:Amgen: Consultancy, Honoraria, Research Funding; Celgene: Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria; Genesis: Consultancy, Honoraria, Research Funding; Novartis: Honoraria. Hungria:Takeda: Consultancy; Roche: Consultancy; International Myeloma Foundation Latin America: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Speakers Bureau; Bristol: Consultancy; Amgen: Consultancy. Mateos:Takeda: Honoraria; Amgen: Honoraria; Janssen: Honoraria; Celgene: Honoraria. Cook:Bristol-Myers Squibb: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; Glycomimetics: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; Sanofi: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau. Leleu:Novartis: Honoraria; LeoPharma: Honoraria; Pierre Fabre: Honoraria; Amgen: Honoraria; Bristol-Myers Squibb: Honoraria; Takeda: Honoraria; Celgene: Honoraria; Janssen: Honoraria; TEVA: Membership on an entity's Board of Directors or advisory committees. Goldschmidt:Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding; Chugai: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Millennium: Membership on an entity's Board of Directors or advisory committees, Research Funding; Onyx: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees. Seal:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment, Equity Ownership. Pashos:Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment. Stull:Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment. Romanus:Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment. Cacioppo:Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment. Bell:Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment, Equity Ownership. Yu:Takeda Restricted Stock Unit (RSU), a publicly traded company: Equity Ownership; Takeda Development Center Americas, Inc., Deerfield, IL, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment. Luptakova:Takeda Oncology: Employment. Niculescu:Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment. Noga:Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment, Equity Ownership. Skacel:Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment. Chari:Array Biopharma: Consultancy, Research Funding; Amgen Inc.: Honoraria, Research Funding; Celgene: Consultancy, Research Funding; Takeda: Consultancy, Research Funding; Pharmacyclics: Research Funding; Novartis: Consultancy, Research Funding; Janssen: Consultancy, Research Funding.
31
Ren, Jia, Jing Zhang, and Yani Cui. "Autonomous Obstacle Avoidance Algorithm for Unmanned Surface Vehicles Based on an Improved Velocity Obstacle Method." ISPRS International Journal of Geo-Information 10, no. 9 (September 16, 2021): 618. http://dx.doi.org/10.3390/ijgi10090618.
Full textAbstract:
Focusing on the collision avoidance problem for Unmanned Surface Vehicles (USVs) in the scenario of multi-vessel encounters, a USV autonomous obstacle avoidance algorithm based on the improved velocity obstacle method is proposed. The algorithm is composed of two parts: a multi-vessel encounter collision detection model and a path re-planning algorithm. The multi-vessel encounter collision detection model draws on the idea of the velocity obstacle method through the integration of characteristics such as the USV dynamic model in the marine environment, the encountering vessel motion model, and the International Regulations for Preventing Collisions at Sea (COLREGS) to obtain the velocity obstacle region in the scenario of USV and multi-vessel encounters. On this basis, two constraint conditions for the motion state space of USV obstacle avoidance behavior and the velocity obstacle region are added to the dynamic window algorithm to complete a USV collision risk assessment and generate a collision avoidance strategy set. The path re-planning algorithm is based on the premise of the minimum resource cost and uses an improved particle swarm algorithm to obtain the optimal USV control strategy in the collision avoidance strategy set and complete USV path re-planning. Simulation results show that the algorithm can enable USVs to safely evade multiple short-range dynamic targets under COLREGS.
32
Wiegers, Ann L. "Valid Methods: The Quality Assurance of Test Method Development, Validation, Approval, and Transfer for Veterinary Testing Laboratories." Journal of Veterinary Diagnostic Investigation 15, no. 4 (July 2003): 303–10. http://dx.doi.org/10.1177/104063870301500401.
Full textAbstract:
Third-party accreditation is a valuable tool to demonstrate a laboratory's competence to conduct testing. Accreditation, internationally and in the United States, has been discussed previously. However, accreditation is only 1 part of establishing data credibility. A validated test method is the first component of a valid measurement system. Validation is defined as confirmation by examination and the provision of objective evidence that the particular requirements for a specific intended use are fulfilled. The international and national standard ISO/IEC 17025 recognizes the importance of validated methods and requires that laboratory-developed methods or methods adopted by the laboratory be appropriate for the intended use. Validated methods are therefore required and their use agreed to by the client (i.e., end users of the test results such as veterinarians, animal health programs, and owners). ISO/IEC 17025 also requires that the introduction of methods developed by the laboratory for its own use be a planned activity conducted by qualified personnel with adequate resources. This article discusses considerations and recommendations for the conduct of veterinary diagnostic test method development, validation, evaluation, approval, and transfer to the user laboratory in the ISO/IEC 17025 environment. These recommendations are based on those of nationally and internationally accepted standards and guidelines, as well as those of reputable and experienced technical bodies. They are also based on the author's experience in the evaluation of method development and transfer projects, validation data, and the implementation of quality management systems in the area of method development.
33
Wang, Xiaohui, and Gary N. McLean. "The Dilemma of Defining International Human Resource Development." Human Resource Development Review 6, no. 1 (March 2007): 96–108. http://dx.doi.org/10.1177/1534484306296305.
Full text
34
MECHLEM, KERSTIN. "Moving Ahead in Protecting Freshwater Resources: The International Law Commission's Draft Articles on Transboundary Aquifers." Leiden Journal of International Law 22, no. 4 (October 28, 2009): 801–21. http://dx.doi.org/10.1017/s0922156509990239.
Full textAbstract:
AbstractOn 11 December 2008 the UN General Assembly adopted a set of draft articles on the law of transboundary aquifers which had been prepared by the International Law Commission (ILC) between 2002 and August 2008. These draft articles are the first official instrument that lays down rules of international law for the management and protection of groundwater, which makes up 97 per cent of the Earth's freshwater resources, excluding the resources locked in polar ice. This article discusses the contribution of the draft articles to the development of international water law. It first provides some background on the importance of shared groundwater resources, then describes the ILC's work on transboundary aquifers, and finally assesses in detail the draft articles and the way ahead.
35
Lieberman, Lani, Andreas Greinacher, Michael F. Murphy, Tamam Bakchoul, Stacy Corke, Susano Tanael, Mette Kjaer, et al. "Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT): Guidance to Reduce the Risk of Intracranial Bleeding." Blood 132, Supplement 1 (November 29, 2018): 4717. http://dx.doi.org/10.1182/blood-2018-99-109906.
Full textAbstract:
Abstract Introduction FNAIT is associated with severe bleeding, especially intracranial hemorrhage (ICH), in the fetus and/or newborn. More than 75% of ICHs occur in utero and up to 50% before 32 weeks gestation. The consequences of ICH include death (35%) or serious neurological sequelae in survivors (83%). FNAIT requires prompt identification and treatment antepartum, postpartum and in subsequent pregnancies. An international panel was convened by the International Collaboration for Transfusion Medicine Guidelines (ICTMG) to develop evidence based recommendations for diagnosis and management of FNAIT. Methods The international panel consisted of specialists in adult and pediatric hematology, maternal fetal medicine (MFM), neonatology, methodology, transfusion medicine, and a patient representative. Clinical questions were developed for diagnostic testing, antenatal screening and management, and postnatal interventions. A systematic search for articles published between 1946 and June 2017 in MEDLINE, EMBASE and Cochrane was conducted. Recommendations were formulated based on the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method which incorporates the quality of the evidence, benefits and risks, and resource utilization. Web conferences and electronic correspondence were used to discuss the results of the systematic reviews and formulate recommendations. Considerations for clinical practice such as dosing of intravenous immunoglobulin (IVIG) and corticosteroids were detailed. Electronic surveys were sent to all members to assess agreement with recommendations. The final guidance document was sent to maternal fetal, hematology and pediatric societies for comments. Results Three systematic reviews (antenatal management, postnatal management and use of laboratory investigations to identify pregnancies at risk) were developed. Antenatal recommendations: Women with FNAIT in a previous pregnancy or sisters of women with FNAIT should be referred to MFM centers. Fetal HPA typing (e.g. HPA-1a/1b) should be performed in HPA-immunized pregnant women when the paternity is unknown or the partner is heterozygous or unavailable for testing. Prenatal HPA-1 typing should preferentially be performed by a non-invasive method e.g. cell-free fetal DNA (cffDNA) in maternal plasma if adequately quality assured. Antenatal IVIG administration to the mother commencing at 12-16 weeks gestation should be offered to all women in a subsequent pregnancy with maternal fetal incompatibility who have had a previous fetus or neonate with FNAIT related ICH. For all other pregnancies with a previous neonate with FNAIT (without ICH), administering antenatal IVIG to the mother should be discussed prior to a subsequent pregnancy or when pregnancy with maternal fetal incompatibility is confirmed. If corticosteroids are used with IVIG, dexamethasone should not be used because of the associated risk of oligohydramnios. Postnatal recommendations: HPA-selected platelets should be made available at delivery for potentially affected infants to increase the neonatal platelet count. If HPA-selected platelets are not immediately available, unselected platelets should be used. In the presence of life-threatening neonatal hemorrhage such as intracranial or gastrointestinal bleeding, platelets should be transfused to maintain platelet counts above 50 to 100x109/L for at least 7 days. In the absence of life-threatening bleeding in a neonate such as intracranial or gastrointestinal bleeding, platelets should be transfused to maintain a platelet count above 30x109/L. Conclusions The intent of this guidance document developed from systematic reviews is to promote best practices in the management of FNAIT. The guideline development group developed algorithms for treatment, podcasts for physicians and patients, pamphlets for patients and a slide set to assist with the implementation of recommendations into practice. This expert panel identified key areas for future research. One is the optimal approach to antenatal management of the next affected pregnancy. Developing biomarkers of fetal severity would be critical to this endeavor. In addition, creating comprehensive screening to identify HPA-1b1b women at risk of FNAIT would advance successful prevention of this disease. Disclosures Bakchoul: German Research Society (DFG): Research Funding; Aspen Germany gGmbH, CLS Behring, Stago gGmbH: Honoraria; Robert Bosch gGmbH: Research Funding. Kjaer:Prophylix Pharma: Equity Ownership. Kjeldsen-Kragh:Prophylix Pharma: Equity Ownership. Oepkes:Towards routine HPA screening in pregnancy: Research Funding. Bussel:Uptodate: Honoraria; Rigel: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Protalex: Consultancy; Amgen Inc.: Consultancy, Research Funding; Prophylix: Consultancy, Research Funding; Momenta: Consultancy. Arnold:Bristol Myers Squibb: Research Funding; Amgen: Consultancy, Research Funding; UCB: Consultancy; Novartis: Consultancy, Research Funding; Bristol Myers Squibb: Research Funding; UCB: Consultancy; Novartis: Consultancy, Research Funding; Amgen: Consultancy, Research Funding. Savoia:Neonatal Alloimmune Thrombocytopenia Registry of the Transfusion Outcomes Research Collaborative (TORC) Australia: Membership on an entity's Board of Directors or advisory committees.
36
Van Wart, Montgomery, and N. Joseph Cayer. "Introduction: Human resource development symposium." International Journal of Public Administration 19, no. 5 (January 1996): 591–98. http://dx.doi.org/10.1080/01900699608525111.
Full text
37
Yang, Rongxin. "Yunnan.s Water Resource Development." China Report 42, no. 1 (February 2006): 25–39. http://dx.doi.org/10.1177/000944550504200102.
Full text
38
Swartzburg, Susan G. "Resources for the conservation of Southeast Asian art." Art Libraries Journal 18, no. 2 (1993): 39–43. http://dx.doi.org/10.1017/s0307472200008336.
Full textAbstract:
There is a desperate and urgent need to conserve works of art and documentary materials in Southeast Asia, where the rigours of the climate and the effects of war and political unrest have ravaged the cultural heritage. An initiative launched by Cornell University in Cambodia, with the intention of preserving documentary materials and training Cambodian librarians in conservation techniques, may result in the development of a badly-needed regional centre which would complement the National Archives of the Philippines, and the Regional Conservation Centres established by IFLA on the Pacific rim, in Australia and Japan. Information and expertise are available from UNESCO, ICOMOS, ICCROM, ICOM, the Getty Conservation Institute, IIC, IADA, IPC, IFLA, ICA, and other international and US organisations.
39
Tillett, Barbara B. "The International Development of RDA: Resource Description and Access." Alexandria: The Journal of National and International Library and Information Issues 24, no. 2 (August 2013): 1–10. http://dx.doi.org/10.7227/alx.0004.
Full text
40
HU, Hao, Hiroshi ONODA, Kenichi NAKAJIMA, and Katsuya NAGATA. "Development of a Traceability System for International Resource Recycling." Resources Processing 57, no. 2 (2010): 53–60. http://dx.doi.org/10.4144/rpsj.57.53.
Full text
41
Pocztowski, Aleksy. "Adding Value from Human Resource Development in International Assignments." Argumenta Oeconomica Cracoviensia, no. 9 (2013): 9–28. http://dx.doi.org/10.15678/aoc.2013.0901.
Full text
42
O’Sullivan, Sharon L. "International human resource management challenges in Canadian development INGOs." European Management Journal 28, no. 6 (December 2010): 421–40. http://dx.doi.org/10.1016/j.emj.2010.06.006.
Full text
43
Yamashita, Kiyonobu, Akio Toba, and Masashi Nakazono. "International deployment of nuclear human resource development network activities." Journal of the Atomic Energy Society of Japan 62, no. 9 (2020): 532–34. http://dx.doi.org/10.3327/jaesjb.62.9_532.
Full text
44
Kitchener, Henry Charles, William Hoskins, William Small, Gillian M. Thomas, and Edward Lloyd Trimble. "The Development of Priority Cervical Cancer Trials: A Gynecologic Cancer InterGroup Report." International Journal of Gynecologic Cancer 20, no. 6 (July 2010): 1092–100. http://dx.doi.org/10.1111/igc.0b013e3181e730aa.
Full textAbstract:
Since the late 1990s, when a spate of US studies reported the benefit of chemoradiation for cervical cancer, there has been a dearth of clinical trials in cervical cancer. This requires to be addressed with urgency because this disease is responsible for a quarter of a million deaths globally each year, mostly in developing countries, but therapeutic advances are required in all health care settings.The Gynecologic Cancer InterGroup (GCIG) is a worldwide collaborative of leading national groups that develops and promotes multinational trials in gynecologic cancer. In recognition of the pressing need for action, the GCIG convened an international meeting with expert representations from most of the GCIG groups and selected large centers in low- and middle-income countries. The focus was to identify consensus on several concepts for clinical trials, which would be developed and promoted by the GCIG and launched with major international participation.The first half of the meeting was devoted to a resume of the current state of the knowledge and identifying the gaps most needing new evidence. The second half of the meeting was concerned with achieving consensus on the way forward. There were 2 principal outcomes. The first was a proposal to establish, under the umbrella of GCIG, a cervical cancer trials network of centers from countries currently outside GCIG (Eastern Europe, India, Thailand, Southern Africa, and South and Central America), which could increase international participation in trials, conducted within the principles of good clinical practice. The second was to identify the priorities for clinical trials. These included additional systemic therapy before or after chemoradiation; less radical surgery for small, early-stage tumors; the use of fewer fractions to improve cost-effectiveness of treatment in centers with limited resources; and chemotherapy to improve resectability of bulky tumors.
45
Laurikka-Routti, Marjut, Maija Haukkamaa, and Pekka Lähteenmäki. "Suppression of ovarian function with the transdermally given synthetic progestin ST 1435**ST 1435 was donated by The Population Council, Inc., New York, New York. This work was undertaken as part of the Contraceptive Development Program sponsored and coordinated by the International Committee for Contraception Research of the Population Council, Inc., New York, New York. The financial support provided by the George J. Hecht Fund, The Mellon Foundation, The Rockefeller Foundation, and the United States Agency for International Development through The Population Council, Inc., New York, New York, as well as the Finnish Gynecological Association, Helsinki, Finland, is greatly acknowledged. The content of this report does not necessarily reflect the policy of any of the funding resources." Fertility and Sterility 58, no. 4 (October 1992): 680–84. http://dx.doi.org/10.1016/s0015-0282(16)55311-4.
Full text
46
Havro, Gøril, and Javier Santiso. "Benefiting the Resource Rich: How Can International Development Policy Help Tame the Resource Curse?" IDS Working Papers 2011, no. 355 (January 2011): 01–54. http://dx.doi.org/10.1111/j.2040-0209.2011.00355_2.x.
Full text
47
Jaiswal, Mayank, and Robert Maxwell. "The trials and tribulations of JTH Inc." CASE Journal 15, no. 2 (March 30, 2019): 88–108. http://dx.doi.org/10.1108/tcj-06-2018-0065.
Full textAbstract:
Theoretical basis The theoretical linkages are with dynamic nature of PESTEL analysis, Porter’s five forces, resource-based view of the firm and characteristics of an entrepreneur. Research methodology The names of the institutions and individuals involved have been disguised. However, the material facts of the case are authentic. Case overview/synopsis This case discusses strategy in the context of a crisis situation in a small business. JTH Inc. was a computer subcontract manufacturing (SCM) firm serving the New England region of the USA. The influx of international competition (mainly from China) due to recession led to significant challenges for JTH and the SCM industry. JTH was struggling and the situation was further complicated by the founder’s (Robert Maxwell) personal and emotional situation. Robert had to decide whether to keep the business running, close it down, merge with/be acquired by a competitor, innovate the business model or do something else. Complexity academic level This case is designed to target undergraduate students of Strategic Management; it may also include Entrepreneurship students. It should most probably be taught in the first half of the course after concepts such as PESTEL, Porter and resource-based view of the firm have been taught.
48
Lamb, Charles A. "Blueprinting the Future: Strategy Development at Allied Signal, Inc." Journal of Business & Industrial Marketing 5, no. 1 (January 1990): 41–47. http://dx.doi.org/10.1108/eum0000000002736.
Full text
49
Chao, Chun R., Lanfang Xu, Nancy Cannizzaro, Angie Mae Rodday, Joseph Feliciano, Anita J. Kumar, Andrew M. Evens, and Susan K. Parsons. "The Development and Validation of an Electronic Health Record (EHR)-Based Algorithm for Identifying Treatment Failure in Newly Diagnosed Hodgkin Lymphoma (HL) Treated in a US Community Oncology Setting." Blood 132, Supplement 1 (November 29, 2018): 2261. http://dx.doi.org/10.1182/blood-2018-99-112225.
Full textAbstract:
Abstract Introduction Most existing cancer registries do not fully capture relapse or progression of cancer. Further, clinical trials for upfront treatment typically withdraw patients from study at the time of treatment failure and only collect minimal information about approaches to and outcomes with salvage therapy. As such, patient outcomes other than mortality often are available only through formal chart review, which is resource intensive. For HL, although many patients are successfully cured, a sizeable subset of patients experience treatment failure. Most of the data describing failure arises from prospective clinical trials, despite most patients receiving treatment in the community setting. Therefore, data from the community setting are needed to understand the experience of real-world patients and to inform and improve the quality of care in oncology practices. To facilitate observational research and quality improvement projects on HL treatment failure, we examined an EHR-based algorithm for identifying treatment failure in HL. Methods All HL patients who initially presented with advanced stages II-IV disease between 2007-2012 at Kaiser Permanente Southern California (KPSC) were identified using KPSC's cancer registry. An algorithm for identifying treatment failure was proposed by study oncologists. Treatment failure was defined as relapse after complete remission of > 60 days' duration or disease progression on active treatment. The algorithm was defined as meeting one of the following: (1) Initiation of any second chemotherapy regimen, including use of brentuximab vedotin, or PD-1 inhibitor beyond initial regimen; or (2) stem cell transplantation (SCT). Data needed to construct the algorithm were collected from KPSC's EHR, including the chemotherapy database and transplant registry. The algorithm was applied to all HL cases up to 4 years after diagnosis, as most HL relapses occur within this timeframe. Manual chart reviews were performed for all potential treatment failure cases identified by the algorithm, and for one-third of randomly-selected HL cases not captured by the algorithm. Each case was abstracted by trained study staffed and reviewed for quality control by two study oncologists. Results Of the 470 HL patients newly diagnosed during the study period (91% diagnosed at age 18 and older, 57% male), the algorithm identified 80 as potential treatment failure cases. Chart review confirmed 75 of 80 as actual treatment failure. The algorithm misclassified relapse for 5 cases who had emergence of a second malignancy for which therapy was instituted after the completion of initial therapy for HL. The positive predictive value (PPV) was 94% (95% confidence interval: 89%-99%). The negative predictive value (NPV) based on the review of 127 patients not captured by the algorithm was 100%. Based on the high PPV and NPV, our review suggested both a high sensitivity and specificity of the algorithm. Conclusion This EHR-based algorithm, based on receipt of second-line therapy beyond initial treatment and SCT, was highly effective in capturing relapse or disease progression cases among HL patients in this integrated health care delivery system. Application of this algorithm will allow for better long-term follow up for novel agents in observational studies, which is critical for understanding the cost-effectiveness of therapeutic agents in real-world patients. External validation using data from other health care settings or sources such as claims data will be useful to further confirm the generalizability of this algorithm. Altogether, this algorithm could assist practices in the identification and prospective tracking of the relapsed/refractory HL patient population for clinical and non-clinical outcomes, such as cost, health-related quality of life, and sequelae of treatment. Disclosures Chao: Seattle Genetics: Research Funding. Xu:Seattle Genetics: Research Funding. Cannizzaro:Seattle Genetics: Research Funding. Rodday:Seattle Genetics: Research Funding. Feliciano:Seattle Genetics: Employment, Equity Ownership. Kumar:Seattle Genetics: Research Funding. Evens:Seattle Genetics, Inc.: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics International DMC: Membership on an entity's Board of Directors or advisory committees; Tesaro: Research Funding; Abbvie: Consultancy; Janssen: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; Affimed: Consultancy; Novartis: Consultancy; Acerta: Consultancy; Bayer: Consultancy. Parsons:Seattle Genetics: Research Funding.
50
&, Leonard Nadler, Garland D. Wiggs, and STUART SMITH. "Managing Human Resource Development." R&D Management 18, no. 3 (July 1988): 289. http://dx.doi.org/10.1111/j.1467-9310.1988.tb00600.x.
Full text